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Abstract
Before birth, glucocorticoids retard growth, although the extent to which this is mediated by changes in insulin signalling
pathways in the skeletal muscle of the fetus is unknown. The current study determined the effects of endogenous and
synthetic glucocorticoid exposure on insulin signalling proteins in skeletal muscle of fetal sheep during late gestation.
Experimental manipulation of fetal plasma glucocorticoid concentration was achieved by fetal cortisol infusion and
maternal dexamethasone treatment. Cortisol infusion significantly increased muscle protein levels of Akt2 and
phosphorylated Akt at Ser473, and decreased protein levels of phosphorylated forms of mTOR at Ser2448 and S6K at
Thr389. Muscle GLUT4 protein expression was significantly higher in fetuses whose mothers were treated with
dexamethasone compared to those treated with saline. There were no significant effects of glucocorticoid exposure on
muscle protein abundance of IR-b, IGF-1R, PKCf, Akt1, calpastatin or muscle glycogen content. The present study
demonstrated that components of the insulin signalling pathway in skeletal muscle of the ovine fetus are influenced
differentially by naturally occurring and synthetic glucocorticoids. These findings may provide a mechanism by which
elevated concentrations of endogenous glucocorticoids retard fetal growth.
Citation: Jellyman JK, Martin-Gronert MS, Cripps RL, Giussani DA, Ozanne SE, et al. (2012) Effects of Cortisol and Dexamethasone on Insulin Signalling Pathways in
Skeletal Muscle of the Ovine Fetus during Late Gestation. PLoS ONE 7(12): e52363. doi:10.1371/journal.pone.0052363
Editor: Josep V. Planas, Universitat de Barcelona, Spain
Received November 7, 2011; Accepted November 16, 2012; Published December 26, 2012
Copyright:  2012 Jellyman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by the Biotechnology and Biological Sciences Research Council and Tommy’s the Baby Charity, UK. SEO is a British Heart
Foundation Senior Fellow. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of this manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ajf1005@cam.ac.uk
Introduction
In all species studied to date, there is an increase in the
circulating glucocorticoid concentration in the fetus near term [1].
Glucocorticoids such as cortisol promote differentiation of specific
cell types in fetal tissues at the expense of cell proliferation and
growth. They are thereby responsible for both the normal decrease
in fetal growth rate that occurs near term and the prepartum
maturation of tissues essential for the successful transition from the
intrauterine to the extrauterine environment at birth, including
insulin-sensitive tissues such as skeletal muscle [1,2]. The
maturational properties of glucocorticoids are beneficial in clinical
practice where synthetic glucocorticoids such as dexamethasone
are routinely administered to pregnant women at risk of preterm
delivery in order to accelerate fetal maturation and improve
survival and health outcomes of the premature neonate [3].
However, exposure of the fetus to antenatal glucocorticoid
treatment, and endogenous glucocorticoids elevated in response
to suboptimal intrauterine conditions, may impair fetal growth
and alter insulin sensitivity and glucose metabolism in the adult
animal [4,5,6].
The insulin receptor (IR) and insulin-like growth factor type 1
receptor (IGF-1R) are members of the family of receptor tyrosine
kinases. When activated by insulin or IGFs, these kinases
phosphorylate insulin receptor substrates (IRS) which, in turn,
lead to the activation of a number of cascades, including the
phosphophatidylinositol 3-kinase (PI3K) signalling pathway. This
pathway can induce Akt phosphorylation which induces tissue-
specific metabolic effects, such as translocation of the glucose
transporter-4 (GLUT4) and consequently stimulation of glucose
uptake in skeletal muscle and adipose tissue, activation of the
peroxisome proliferator activated receptors involved in fat
metabolism and storage, and stimulation of glycogen synthase
activity and glycogen deposition in skeletal muscle and liver [7,8].
Activation of the PI3K pathway also leads to phosphorylation of
mammalian target of rapamycin (mTOR) which controls the
phosphorylation rate of proteins such as ribosomal protein S6
kinase (S6K) that in turn promotes protein translation [7,8]. Tissue
mTOR expression thereby has an important role in the
coordination of nutrient status, protein synthesis and tissue growth
[9,10].
In fetal life, insulin has both glucoregulatory and anabolic
actions from at least mid-gestation and developmental changes in
the expression of insulin receptors and intracellular signalling
proteins have been observed in fetal tissues, including skeletal
muscle [11–14]. For example, the expression of GLUT4 in skeletal
muscle of rats and baboons is lower in fetal compared to adult life
and increases with gestational age [13,14]. However, little is
PLOS ONE | www.plosone.org 1 December 2012 | Volume 7 | Issue 12 | e52363
known about the regulation of insulin signalling pathways by
glucocorticoids before birth. Therefore, the aim of the present
study was to determine the effect of endogenous and synthetic
glucocorticoids on the expression of insulin signalling proteins in
skeletal muscle of fetal sheep. Glucocorticoid exposure in utero was
hypothesised to decrease the abundance of proteins associated
with growth, such as mTOR and S6K, and increase the proteins
associated with glucose transport, such GLUT4. These changes
may be responsible for the decline in fetal growth towards term
and the preparation for greater dependence on insulin-stimulated
glucose disposal after birth, respectively. Experimental manipula-
tions of fetal plasma concentrations of glucocorticoid were
achieved by fetal cortisol infusion and maternal dexamethasone
treatment. These two experimental models enabled the impact of




Twenty-one Welsh Mountain sheep fetuses of known gestational
age were used in this study; all were singleton fetuses (13 male and
8 female). The ewes were housed in individual pens and fed
concentrates (200 g day21; 18% protein and 10 MJ kg21; Sheep
Nuts #6; H&G Beart, Kings Lynn, UK) with free access to hay,
water and a salt-lick block. Overall, the pregnant ewes consumed
between 8–11 MJ day-1 of metabolizable energy. Food, but not
water, was withheld for 18–24 h before surgery. All surgical and
experimental procedures were conducted in accordance with the
UK Animals (Scientific Procedures) Act 1986 and were approved
by the University of Cambridge animal ethics committee.
Surgical and Experimental Procedures
Fetal cortisol infusion. Under halothane anesthesia (1.5%
in O2-N2O), catheters were implanted into the femoral artery and
vein of eleven fetuses at 115–117 days of gestation using surgical
methods described previously (term 14562 days) [15]. Blood
samples (2 ml) were taken daily throughout the experimental
period from the catheterized fetuses to monitor fetal blood gas
status. At least six days after catheterization, the fetuses were
infused intravenously with either cortisol (2–3 mg kg21day21 in
3.0 ml 0.9% saline; EF-Cortelan, GlaxoSmithKline, Brentford,
Middlesex, UK; n = 5) or the saline vehicle (3.0 ml day21 0.9%
wt/vol; n = 6) for five days beginning at 125–126 days of gestation.
The dose of cortisol was chosen to mimic the plasma concentra-
tions normally observed in the immediate prepartum period in
fetal sheep [1].
Maternal dexamethasone treatment. In a separate cohort
of animals, ten un-operated pregnant ewes were injected twice i.m.
with either dexamethasone (12 mg dexamethasone sodium phos-
phate; Merck Sharpe and Dohme Ltd, Hoddesdon, Herts, UK;
n = 5) in 2 ml saline or the saline vehicle (0.9% w/v NaCl; n = 5) at
24 hour intervals from 125 days of gestation. Tissues were
collected 10 hours after the final maternal injection. The
dexamethasone treatment regime resembles that recommended
for use in human clinical practice [16].
Blood and Tissue Collection
All fetuses were delivered by Caesarean section under general
anaesthesia of the ewe (20 mg kg21 sodium pentobarbitone i.v.).
At delivery, a 10 ml blood sample was taken by venepuncture of
the umbilical artery, and a number of tissues were collected from
the fetus after the administration of a lethal dose of barbiturate
(200 mg kg21 sodium pentobarbitone). Skeletal muscle tissue
samples taken from the hind limb (biceps femoris) were
immediately frozen in liquid nitrogen and stored at 280uC until
analysis. All blood samples obtained at tissue collection were
immediately placed into EDTA-containing tubes and centrifuged
for 5 min at 1000 x g and 4uC. The plasma aliquots were stored at
–20uC until analysis.
Biochemical Analyses
Plasma cortisol concentration was measured in the umbilical
arterial sample by radioimmunoassay validated for use with ovine
plasma [17]. The lower limit of detection was 1.0–1.5 ng.ml21,
and the inter-assay coefficient of variation was 12%.
Muscle protein levels were quantified by Western blotting using
methods described previously [18,19]. The antibodies used in this
study were to IR-b subunit, IGF-1R, PKCf, Akt1, Akt2, p-Akt
Ser473, p-mTOR Ser2448, p-S6K Thr389, calpastatin and
GLUT4 (Table 1), and have been used previously in this
laboratory to quantify protein levels in the skeletal muscle of fetal
sheep [20]. Horseradish peroxidase-conjugated secondary anti-
bodies to the host species were used as appropriate and antibody
binding was detected using an enhanced chemiluminescence kit
(all products from GE Healthcare Life Sciences, Little Chalfont,
Bucks, UK). Protein expression was quantified using Image J
software (National Institutes of Health, Bethesda, MD; http://rsb.
info.nih.gov/ij/).
The glycogen content of skeletal muscle was determined by a
biochemical assay as described previously [21]. The inter-assay
coefficient of variation was 9%.
Statistical Analyses
Values are presented as mean values 6 SEM. Data were
analysed using Student’s t-test. Ratios of muscle protein expression
were arcsine transformed prior to statistical analysis, and are
presented as a fold change from the mean values observed in the
respective control group. For all comparisons, statistical signifi-
cance was accepted when P,0.05.
Results
Fetal Cortisol Infusion
Plasma cortisol concentration was significantly higher in the
cortisol-infused fetuses than in the saline-infused fetuses (p,0.05;
Table 2). Fetal cortisol infusion for five days led to significant
increases in the muscle protein level of p-Akt Ser473 and the
expression of Akt2 (p,0.05), but not Akt1 (Figure 1A, B and C),
and decreases in the protein expression of p-mTOR Ser2448 and
p-S6K Thr389 (p,0.05; Figure 2A and B). There were no
significant differences in muscle protein abundance of IR-b, IGF-
1R, PKCf, calpastatin (Table 2) or GLUT4 (Figure 3B), or muscle
glycogen content (Table 2), between the saline and cortisol-treated
fetuses.
Maternal Dexamethasone Treatment
At delivery, plasma cortisol concentration was significantly
lower in fetuses whose mothers were injected with dexamethasone
compared to those whose mothers were treated with saline
(p,0.05; Table 2). Exposure of fetuses to dexamethasone caused a
significant increase in muscle GLUT4 protein content (p,0.05;
Figure 3B). However, fetal muscle protein levels of IR-b, IGF-1R,
PKCf, calpastatin (Table 2), Akt 1, Akt2 and p-Akt Ser473
(Figure 1D, E and F), p-mTOR Ser2448 and p-S6K Thr389
(Figure 2C and D), and muscle glycogen content (Table 2) were
not significantly different between the saline and dexamethasone-
treated animals.
Glucocorticoids and Insulin Signalling In Utero
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Discussion
The results demonstrate that components of the insulin
signalling pathways relating to both growth and glucoregulation
in skeletal muscle of the ovine fetus are sensitive to glucocorticoid
exposure in utero. In agreement with the hypothesis of the study,
fetal infusion of cortisol led to downregulation of the phosphor-
ylated levels of the anabolic proteins, mTOR and S6K, while
maternal dexamethasone treatment increased GLUT4 expression
in fetal skeletal muscle.
These findings contribute to the understanding of the regulation
of growth by glucocorticoids in utero. In fetal sheep, the decline in
growth rate seen near term is known to be glucocorticoid-
dependent, since it can be prevented by removal of the fetal
adrenal gland and induced prematurely by five days of cortisol
infusion [2]. Reductions in the phosphorylated levels of mTOR
and S6K induced by cortisol in skeletal muscle of the ovine fetus
may be one mechanism by which glucocorticoids retard muscle
protein synthesis and overall fetal growth. Indeed, glucocorticoids
have been shown previously to decrease S6K phosphorylation and
Table 1. Details of the antibodies used in Western blotting.
Protein Antibody Dilution Source Catalogue Number
IR-b Rabbit polyclonal 1:200 Santa Cruz Biotechnologies, Santa Cruz, CA, USA sc711
IGF-1R Rabbit polyclonal 1:200 As above. sc713
PKCf Rabbit polyclonal 1:500 As above. sc216
p-Akt Ser473 Rabbit monoclonal 1:1000 Cell Signaling Technology, Inc, Beverly, MA, USA 4058
Akt1 Mouse monoclonal 1:1000 As above. 2967
Akt2 Rabbit monoclonal 1:1000 As above. 3063
p-mTOR Ser2448 Rabbit polyclonal 1:1000 As above. 2971
p-S6K Thr389 Rabbit polyclonal 1:1000 As above. 9205
Calpastatin Chicken polyclonal 1:1000 Abcam, Cambridge, UK ab16423
GLUT4 Rabbit polyclonal 1:4000 As above. ab654
doi:10.1371/journal.pone.0052363.t001
Figure 1. Mean (± SEM) protein levels of (A, D) p-Akt, (B, E) Akt1 and (C, F) Akt2 in skeletal muscle of fetuses infused i.v. with either
saline or cortisol for 5 days, and fetuses whose mothers were injected i.m. with either saline or dexamethasone. *, significantly
different from saline control group, p,0.05.
doi:10.1371/journal.pone.0052363.g001
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protein synthesis in cultured L6 myoblasts and in rat skeletal
muscle in vivo [22,23].
In the present study, reductions in muscle p-mTOR and p-S6K
in the cortisol-infused fetuses were associated with increased Akt2
and p-Akt protein content. This finding was unexpected given that
the PI3K/Akt pathway is a key activator of mTOR phosphory-
lation in adult tissues [7,8]. It is possible that the relative levels of
phosphorylation of Akt at Ser473 and Thr308 may change in
response to glucocorticoid treatment with consequences for the
specificity of downstream targets. Consistent with this possibility, a
recent study in the Jeg-3 human choriocarcinoma cell line has
shown that an increase in Akt phosphorylation at Ser473, induced
Figure 2. Mean (± SEM) protein levels of (A, C) p-mTOR and (B, d) p-S6K in skeletal muscle of fetuses infused i.v. with either saline
or cortisol for 5 days, and fetuses whose mothers were injected i.m. with either saline or dexamethasone. *, significantly different from
saline control group, p,0.05.
doi:10.1371/journal.pone.0052363.g002
Table 2. Mean (6 SEM) plasma concentrations of cortisol, muscle protein levels of IR-b, IGF-1R, PKCf and calpastatin, and muscle
glycogen content in fetuses infused i.v. with either saline or cortisol for 5 days, and in fetuses whose mothers were injected i.m.
with either saline or dexamethasone.
Fetal administration Maternal administration
Saline Cortisol Saline Dexamethasone
Gestational age (days) 13060 13160.2 12760 12760
Plasma cortisol (ng.ml21) 14.162.0 91.2620.9* 16.162.8 8.660.7*
Muscle IR-b (au) 1.0060.20 1.1160.10 1.0060.06 0.8860.06
Muscle IGF-1R (au) 1.0060.21 1.0660.13 1.0060.16 0.8460.13
Muscle PKCf (au) 1.0060.09 0.8660.06 1.0060.03 1.0260.04
Muscle calpastatin (au) 1.0060.09 0.8360.10 1.0060.04 1.0760.13
Muscle glycogen (mg.g tissue21) 46.2763.72 48.3862.21 48.7061.95 50.5163.14
*, significantly different from the respective saline control group, Student’s t-test, p,0.05. IR-b, insulin receptor b-subunit; IGF-1R, insulin-like growth factor-1 receptor;
PKCf, protein kinase C f; au, arbitrary units.
doi:10.1371/journal.pone.0052363.t002
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by endoplasmic reticulum stress, decreases phosphorylation of
mTOR at Ser2448 while increasing phosphorylation of other
protein targets [24]. In addition, cortisol may influence p-mTOR
and p-S6K expression independently of the PI3K/Akt pathway
and/or downstream of these proteins in fetal skeletal muscle. For
example, glucocorticoids have been shown to suppress mTOR
levels, at least in part, by activation of the translation repressor
protein REDD1 in cultured L6 myoblasts and in rat skeletal
muscle in vivo [25]. There is also evidence to suggest that mTOR
has negative feedback effects on Akt phosphorylation. Inhibition of
mTOR using rapamycin or its derivatives upregulates Ser473
phosphorylation of Akt in cancer cell lines and human tumours
[26,27]. Of the three isoforms of Akt, Akt2 is highly expressed in
insulin-sensitive tissues, such as skeletal muscle, and previously,
increased Akt2 expression has been associated with increased
myoblast differentiation in vitro [28,29]. In the present study,
however, the tissues were not examined histologically and the
effect of cortisol exposure on the structural development of the
biceps femoris in utero remains unclear.
Muscle GLUT4 protein expression in the ovine fetus was
increased by maternal dexamethasone treatment. This observation
confirms that previously reported in fetuses of pregnant ewes
treated with either single or repeated doses of dexamethasone at
an earlier gestational age (106–107 days) [30]. Dexamethasone has
also been shown to increase GLUT4 protein levels in cultured L6
myoblasts and in rat skeletal muscle in vivo [31,32]. Upregulation
of muscle GLUT4 in the sheep fetus by maternal dexamethasone
treatment occurred without any effect on other components of the
insulin signalling pathway, such as p-Akt and PKCf. Muscle
GLUT4 content in the fetus may be influenced by insulin-
independent as well as insulin-dependent mechanisms. For
example, in fetal sheep, both experimental conditions of hyper-
glycaemia-euinsulinaemia and hyperinsulinaemia-euglycaemia in-
crease GLUT4 protein expression in skeletal muscle in a time-
dependent manner [33]. Despite the increase in muscle GLUT4
protein level observed in the sheep fetuses exposed to dexameth-
asone, there were no changes in muscle glycogen although
glycogen deposition also depends on intracellular glucose avail-
ability, as well as the activities of glycogen synthase and
phosphorylase enzymes which were not determined in the present
study. Furthermore, the extent to which GLUT4 translocation to
the muscle plasma membrane is affected by glucocorticoids in utero
remains unknown.
Cortisol and dexamethasone exerted different effects on muscle
insulin signalling proteins in the fetuses of the two experimental
models of intrauterine glucocorticoid exposure. There are several
possible explanations for these observations. First, the experimen-
tal models differ in the duration and level of glucocorticoid
exposure and timing of tissue collection. In the dexamethasone-
treated animals, dexamethasone concentrations in the fetal
circulation are significantly elevated 1–2 h post-injection and,
although still detectable, fall thereafter at tissue and blood
collection at 10 hours after the second maternal injection [34],
whereas cortisol-treated fetuses were exposed to elevated and
stable levels of glucocorticoid for five days prior to tissue collection.
In both models, there may have been dynamic changes in insulin
signalling protein expression over the time course of each
treatment.
Second, natural and synthetic glucocorticoids differ in their
properties of action. The synthetic glucocorticoids have longer
half-lives and are more potent than the endogenous glucocorti-
coids, and, unlike the endogenous glucocorticoids that act on both
glucocorticoid and mineralocorticoid receptors, synthetic gluco-
corticoids only bind and activate glucocorticoid receptors. The
relative effects of activation of mineralocorticoid receptors by
cortisol on insulin signalling pathways in fetal tissues, however, are
unknown. The fall in plasma cortisol seen in the dexamethasone-
exposed fetuses is in accordance with the negative feedback effects
of synthetic glucocorticoids on endogenous glucocorticoid pro-
duction and has been reported previously in the fetuses of
pregnant ewes treated with dexamethasone [21].
Third, some of the effects of glucocorticoid exposure on insulin
signalling protein expression in skeletal muscle in utero may be due
to concomitant changes in other circulating and/or local
hormones and growth factors. In both of these fetal sheep models,
increases in plasma triiodothyronine and leptin have been
demonstrated in response to fetal cortisol infusion and maternal
dexamethasone treatment [35,36,37]. Although components of the
insulin signalling pathway in fetal skeletal muscle do not appear to
be influenced by leptin treatment in utero [20], the effects of
triiodothyronine are unknown. In addition, previous studies have
shown that maternal dexamethasone treatment in pregnant ewes
causes increases in circulating glucose and insulin in the fetus [21],
while no changes in plasma glucose and insulin are observed after
five days of fetal cortisol infusion [2]. The insulin response to
dexamethasone may negate some of the direct actions of the
glucocorticoid on the insulin signalling proteins as insulin
promotes expression of anabolic proteins, such as S6K, in skeletal
muscle of the ovine fetus [38]. Furthermore, in fetal sheep, both
glucose and insulin are able to upregulate muscle GLUT4 protein
Figure 3. Mean (± SEM) GLUT4 protein level in skeletal muscle
of (a) fetuses infused i.v. with either saline or cortisol for 5
days, and (b) fetuses whose mothers were injected i.m. with
either saline or dexamethasone. *, significantly different from saline
control group, p,0.05.
doi:10.1371/journal.pone.0052363.g003
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expression [33] and, therefore, the dexamethasone-induced
increments in plasma glucose and insulin are likely to contribute
to the increase in muscle GLUT4 seen in the present study.
Suppression of mTOR and S6K in skeletal muscle of cortisol-
treated sheep fetuses may also be due, at least in part, to local
changes in IGF synthesis. Previous studies have shown that cortisol
infusion for five days in fetal sheep downregulates both IGFI and
IGFII mRNA abundance in skeletal muscle [39,40] which may
reduce the anabolic actions of these paracrine agents in the
absence of any change in muscle IGF-1R expression. Muscle IGF
expression has not been measured in the experimental model of
dexamethasone exposure used in the present study, although in
other studies, synthetic glucocorticoid treatment in the pregnant
ewe has been shown to reduce circulating IGFI and IGF binding
proteins in the fetus only after repeated, but not single, doses [41].
Furthermore, in fetal sheep and human infants exposed to
synthetic glucocorticoids in utero, multiple doses lead to impaired
body size at birth while a single dose often has little effect on
growth [42,43].
In summary, the current study demonstrated that endogenous
and synthetic glucocorticoids alter components of the insulin
signalling pathways in skeletal muscle of the ovine fetus in different
ways, with potentially different consequences for the regulation of
muscle growth in the fetus and insulin sensitivity in postnatal life.
An infusion of cortisol to the fetus for five days reduced
phosphorylated levels of mTOR and S6K which, in turn, are
likely to contribute to the mechanisms of glucocorticoid-induced
growth retardation. In contrast, a single course of maternal
dexamethasone treatment had little effect on the insulin signalling
molecules measured in fetal skeletal muscle, apart from an increase
in GLUT4 expression which may be a homeostatic response to the
fetal hyperglycaemia seen previously after dexamethasone expo-
sure [21]. These findings suggest that synthetic glucocorticoid
treatment during pregnancy may have minimal consequence for
insulin signalling and growth of skeletal muscle in the fetus, at least
in the short term.
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